Endocrine Abstracts

Ga-68 PSMA PET/CT is producing images with astounding tumour-to-background contrast for staging prostate cancer. Defining the extent of prostate cancer spread with imaging is of utmost importance for therapeutic decision-making. Relapse following curative-intent treatment is not uncommon despite careful selection of patients with CT, MRI and bone scintigraphy prior to surgery or radiotherapy, highlighting the limited sensitivity of conventional imaging. Imaging with PSMA-PET m...

Ga-68 labelled urea-based inhibitors of the prostate specific membrane antigen (PSMA), such as 68Ga-HBED-PSMA-11, are promising peptides for targeting prostate cancer. The tris(hydroxypyridinone) (THP) ligand rapidly complexes 68Ga3+ at room temperature, at very low concentration and over a wide pH range, making it possible for the direct elution from a 68Ge/68Ga generator into a cold radiopharmaceutical kit in one step wi...